Depleting menaquinone may reverse bedaquiline-resistant tuberculosis

Drug-resistant tuberculosis remains a global health challenge, and bedaquiline has become an important medicine for treating difficult cases. However, some tuberculosis bacteria have evolved ways to resist bedaquiline, including mechanisms that pump the drug out of the cell — so-called efflux-mediated resistance. In work led by Dirk A. Lamprecht, researchers explored a different angle: rather than only looking for new drugs, they tested whether changing the bacteria’s internal chemistry could make resistant bugs vulnerable to bedaquiline again. The team focused on menaquinone, a molecule bacteria use in their energy processes, and investigated what happens when its levels are lowered. The key message from the study is simple and striking: depletion of menaquinone can resensitise bedaquiline-resistant tuberculosis. That finding points to a fresh tactic for dealing with resistance — weaken a bacterial function that supports resistance, and the existing drug regains activity. This approach shifts some attention away from discovering new antibiotics toward making current ones effective again.

Although the abstract provides only a concise summary, the core methods and results are clear. The researchers manipulated menaquinone levels and then tested the response of bedaquiline-resistant tuberculosis to bedaquiline. Across those experiments, depletion of menaquinone was associated with renewed susceptibility to bedaquiline in strains that had been resistant. The study links a biochemical change — lower menaquinone — with restored effectiveness of bedaquiline, and explicitly frames this in the context of efflux-mediated drug-resistant tuberculosis. No additional drug names, genes, or specific laboratory tools are reported in the abstract, but the result is presented as a reproducible biological effect: removing or reducing menaquinone undermines the resistance that had rendered bedaquiline less useful. By demonstrating that resistance can be countered through metabolic intervention, the work provides experimental evidence for a strategy that could complement existing drug-based approaches.

The implications of this finding are practical and strategic. If menaquinone depletion reliably resensitises bedaquiline-resistant tuberculosis, then future treatment regimens could be strengthened by combining bedaquiline with interventions that target menaquinone or the pathways that produce it. This could be especially valuable for efflux-mediated drug-resistant tuberculosis, where traditional methods of overcoming resistance — higher doses or new drugs — have limits. The research suggests a two-pronged approach: continue to use powerful drugs like bedaquiline while also attacking bacterial systems that support resistance. That perspective opens new avenues for drug development, repurposing, or adjunct therapies aimed at bacterial metabolism. The study also signals the need for further work to translate the laboratory finding into safe, effective treatments in people, and to understand whether menaquinone-targeting strategies would be broadly applicable across diverse resistant strains.